2021
“Randomized trial of physical activity on quality of life and lung cancer biomarkers in patients with advanced stage lung cancer: a pilot study”
Bade BC, Gan G, Li F, Lu L, Tanoue L, Silvestri GA, Irwin ML. “Randomized trial of physical activity on quality of life and lung cancer biomarkers in patients with advanced stage lung cancer: a pilot study”. BMC Cancer 2021, 21: 352. PMID: 33794808, PMCID: PMC8015735, DOI: 10.1186/s12885-021-08084-0.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkers, TumorExerciseFemaleHumansLung NeoplasmsMaleNeoplasm StagingPilot ProjectsQuality of LifeConceptsNon-small cell lung cancerAdvanced-stage lung cancerStage lung cancerUsual carePhysical activityIntervention groupQuality of lifeLung cancerEligible patientsStage III/IV non-small cell lung cancerLow baseline physical activityHome-based physical activityAdvanced stage diseaseSoluble PD-1Stage IV adenocarcinomaBaseline physical activityMinority of patientsCell lung cancerPatient-reported outcomesEffects of exerciseRole functioning domainsLung cancer biologyAspects of QoL.Mobile health interventionsCancer biomarkers
2016
Lung cancer screening
Tanoue LT. Lung cancer screening. Current Opinion In Pulmonary Medicine 2016, 22: 327-335. PMID: 27159896, DOI: 10.1097/mcp.0000000000000287.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorEarly Detection of CancerHumansLung NeoplasmsMass ScreeningRadiography, ThoracicTomography, X-Ray ComputedConceptsLung cancer screeningLow-dose chestCancer screeningUS Preventive Services Task ForceNational Lung Screening TrialFuture screening practicesLung cancer mortalityHigh-risk individualsIndividualized risk assessmentTobacco treatmentCancer mortalityFalse-positive resultsLung cancerPositive screenChest radiographyScreening practicesInvasive testingScreening TrialLung cancer biomarkersMultidisciplinary programHigh false positive ratePotential harmOngoing studiesChestRelative reduction
2010
High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology
Anagnostou VK, Lowery FJ, Zolota V, Tzelepi V, Gopinath A, Liceaga C, Panagopoulos N, Frangia K, Tanoue L, Boffa D, Gettinger S, Detterbeck F, Homer RJ, Dougenis D, Rimm DL, Syrigos KN. High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology. BMC Cancer 2010, 10: 186. PMID: 20459695, PMCID: PMC2875218, DOI: 10.1186/1471-2407-10-186.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedBiomarkers, TumorCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCell DifferentiationCohort StudiesConnecticutFemaleGreeceHumansKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedNeoplasm StagingPredictive Value of TestsProportional Hazards ModelsProto-Oncogene Proteins c-bcl-2Reproducibility of ResultsRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUp-RegulationConceptsNon-small cell lung cancer patientsCell lung cancer patientsNon-squamous tumorsLung cancer patientsBcl-2 expressionNSCLC patientsCancer patientsBcl-2Favorable outcomeIndependent cohortSmall cell lung cancer patientsIndependent lower riskNon-squamous histologySubgroup of patientsHigh expressersSquamous cell carcinomaHigh Bcl-2 expressionBcl-2 protein levelsSquamous histologyMedian survivalPrognostic factorsValidation cohortCell carcinomaPathological characteristicsPrognostic stratification
2009
High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma
Anagnostou VK, Bepler G, Syrigos KN, Tanoue L, Gettinger S, Homer RJ, Boffa D, Detterbeck F, Rimm DL. High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma. Clinical Cancer Research 2009, 15: 4157-4164. PMID: 19509151, DOI: 10.1158/1078-0432.ccr-09-0099.Peer-Reviewed Original ResearchConceptsLung cancer patientsMTOR expressionCancer patientsMammalian targetEarly-stage lung adenocarcinomaHigh mTOR expressionIndependent lower riskMedian overall survivalStage IA patientsProtein expressionSubgroup of patientsLung adenocarcinoma patientsStage lung adenocarcinomaMTOR protein expressionRole of mTOROverall survivalPathologic characteristicsPatient survivalValidation cohortAdenocarcinoma groupAdenocarcinoma patientsPrognostic stratificationLung cancerTraining cohortFavorable outcome
1995
Vitamin A Chemoprevention of Lung Cancer
Redlich C, Van Bennekum A, Wirth J, Blaner W, Carter D, Tanoue L, Holm C, Cullen M. Vitamin A Chemoprevention of Lung Cancer. Advances In Experimental Medicine And Biology 1995, 375: 17-29. PMID: 7645426, DOI: 10.1007/978-1-4899-0949-7_2.Peer-Reviewed Original ResearchMeSH KeywordsAnticarcinogenic AgentsBiomarkers, TumorHumansLung NeoplasmsRandomized Controlled Trials as TopicVitamin AConceptsLung cancerParenchymal fibrosisVitamin ABronchoalveolar lavageHigh riskAsbestos-exposed subjectsDouble-blind placeboDietary vitamin ASupplemental vitamin AEffective preventive strategiesPrior clinical studiesPotential early markerProcess of inflammationBiomarkers of susceptibilityBronchial metaplasiaLung inflammationPulmonary cytokinesBronchial biopsiesImmunomodulatory effectsClinical studiesPreventive strategiesHost determinantsHigh incidenceEarly markerFibrosis